Chondrolytic factors expression

Chondrolytic factors expression refers to the pathological production of catabolic enzymes and inflammatory mediators by chondrocytes and synovial cells, leading to the progressive destruction of articular cartilage [1, 11]. This process is a hallmark of degenerative joint diseases such as osteoarthritis (OA) and inflammatory conditions like rheumatoid arthritis (RA) [2, 8]. Key factors involved include matrix metalloproteinases (notably MMP-13, MMP-9, and MMP-3) and aggrecanases (ADAMTS-4 and ADAMTS-5), which degrade the type II collagen and aggrecan components of the cartilage matrix [1, 4]. The expression of these factors is typically induced by pro-inflammatory cytokines, such as interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α), often in response to mechanical overload or joint injury [2, 7]. Therapeutic interventions targeting this process include the use of cytokine inhibitors (e.g., Anakinra, Adalimumab), direct enzyme antagonists (e.g., ONO-4817), and anti-inflammatory agents like corticosteroids [6, 7, 10]. While many agents have shown promise in preclinical models, achieving significant disease-modifying effects in human clinical trials without systemic toxicity remains a major challenge in the field of orthopedics and rheumatology [5, 8].

Other names

Cartilage-degrading factorsCatabolic factors of chondrocytesChondrolytic enzymesMatrix-degrading enzymes

Inhibition of catabolic enzyme activity (MMPs, ADAMTS) or suppression of pro-inflammatory signaling (IL-1, TNF-alpha) that induces their expression.